Based on previous studies, it has been recommended by both the American Diabetes Association and the European Diabetes Association that patients with type 2 diabetes who are at risk for cardiovascular complications should consider taking metformin along with SGLT2 inhibitors and GLP-1 RA. Here, GLP1R is linked to type 2 diabetes mellitus.